KV Pharmaceutical News

Ronald Kanterman has resigned from KV Pharmaceutical Co. 's board of directors, according to a regulatory filing.

Embattled KV Pharmaceutical Co. locked in its interim CEO, David Van Vliet, and the president of the drug company's Ther-Rx Corp.

From Associated Press ST. LOUIS--KV Pharmaceutical Co. said Wednesday it is removing the interim tag from David Van Vliet, making him the company's permanent president and CEO.

ST. LOUIS, Dec. 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company today announced that that it has entered into an employment agreement with Interim President and Chief Executive Officer David A. Van Vliet with a term through December 31, 2011.

The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, small-cap drugmaker KV Pharmaceutical has earned a coveted five-star ranking .

You may never have heard of Arkansas Best , but its 462% gain since the start of 1999 makes it one of the great success stories of the past decade.

KV will receive $14 million from Allegan, Mich.-based Perrigo at closing and an additional $2 million milestone payment upon the completion of a successful technical transfer.

The Navy awarded a bundled $60 million contract to AT&T Inc., Sprint Nextel Corp.

I f you have ever saved a few dollars -- or a lot -- buying generic drugs, give thanks to a law enacted 25 years ago that made it possible.

Perrigo Company today announced that it has purchased the ANDA for clindamycin phosphate and benzoyl peroxide gel from KV Pharmaceutical for $14 million in cash at closing and a $2 million milestone payment upon the completion of a successful technical transfer.

ST. LOUIS, Sept. 15 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company today announced that on September 14, 2009, the Company received an action by written consent of stockholders relating to the adoption by certain stockholders of certain amendments to the Company's By-Laws . A copy of the Written Consent, including the Proposed Amendments, is ...

As fundamentals-focused long-term investors, Fools never base an investment decision on the daily gyrations of the market.

Ilhavo, Portugal a ' 04-09-2009 a ' SADIF Investment Analytics, announces a new summary due diligence report covering K-V Pharmaceutical Company .

ST. LOUIS, Sept, 4 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company today announced that on September 2, 2009, Thomas McHugh, the Vice President of Finance and Corporate Controller of the Company, was named Interim Chief Financial Officer of the Company.

KV Pharmaceutical Co. 's chief financial officer, Ronald Kanterman, stepped down Wednesday, the company said Friday.

The Food and Drug Administration has approved KV Pharmaceutical Co.'s plan to correct manufacturing problems that forced the drugmaker to shut down production earlier this year, KV announced Wednesday.

The biosimilars sector is predicted to be worth $19.4bn by 2014, by which time the US will have overtaken Asia as the dominant market, according to a report.

KV Pharmaceutical Co. has begun rehiring employees to produce test batches of drugs as the company works to regain compliance with the FDA .

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.